Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
11.8 EUR | -0.42% | -1.67% | -7.45% |
Mar. 14 | Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024 | CI |
Mar. 14 | Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024 |
Sales 2024 * | 8.15M 8.75M | Sales 2025 * | 11.95M 12.83M | Capitalization | 332M 356M |
---|---|---|---|---|---|
Net income 2024 * | -14M -15.03M | Net income 2025 * | -18M -19.32M | EV / Sales 2024 * | 39.3 x |
Net cash position 2024 * | 11.6M 12.45M | Net Debt 2025 * | 7M 7.51M | EV / Sales 2025 * | 28.4 x |
P/E ratio 2024 * |
-23.7
x | P/E ratio 2025 * |
-18.1
x | Employees | 42 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 43.38% |
Latest transcript on Hyloris Pharmaceuticals SA
1 day | +0.42% | ||
1 week | -0.83% | ||
Current month | +3.93% | ||
1 month | +7.21% | ||
3 months | -8.81% | ||
6 months | -4.03% | ||
Current year | -6.67% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Jacobsen
FOU | Founder | 50 | 11-12-31 |
Stijn van Rompay
FOU | Founder | 48 | 11-12-31 |
Director of Finance/CFO | 53 | 21-09-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carolyn Myers
BRD | Director/Board Member | 66 | 19-12-31 |
James Gale
BRD | Director/Board Member | 74 | 19-12-31 |
Leon van Rompay
BRD | Director/Board Member | 75 | 19-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 11.8 | -0.42% | 817 |
24-04-25 | 11.85 | -0.84% | 3,406 |
24-04-24 | 11.95 | +2.14% | 4,475 |
24-04-23 | 11.7 | -2.09% | 7,424 |
24-04-22 | 11.95 | -0.42% | 10,433 |
Real-time Euronext Bruxelles, April 26, 2024 at 03:00 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-6.67% | 355M | |
+25.17% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+13.57% | 233B | |
+6.02% | 201B | |
-9.69% | 193B | |
-12.26% | 143B | |
-6.47% | 144B |
- Stock Market
- Equities
- HYL Stock